A Phase 3 interventional study of Ferric Bepectate IV Injection and Ferric Carboxymaltose Injection [Ferinject] in Iron Deficiency Anemia (IDA), sponsored by AFT Pharmaceuticals, Ltd.. Recruiting at 24 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Anemia, Iron-Deficiency with a site in United States — 18 open to participants now, 21 under way, 7 of them phase 3. Anemia, Iron-Deficiency · United States.
Among the 134 studies in Anemia, Iron-Deficiency with a site in United States, this one is the 8th largest by planned enrollment of the 121 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 in phase 3, reaches primary completion later than 15 of the 20 other live ones, and was the 130th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →18 of the 134 studies in Anemia, Iron-Deficiency with a site in United States are open now. Recruiting first, the newest first:
Hemab ApS · Sites in United States
Ages 12–70
AdventHealth · Sites in United States
Ages 29 wk–33 wk
Pennington Biomedical Research Center · Sites in United States
Ages 18–50 · Healthy volunteers
Southern Illinois University · Sites in United States
Ages 18–45 · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 38 · Phase 4 27
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,366 is above the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 51 across the 121 interventional studies, 110 across the 12 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 134 have an industry lead sponsor. The 10 most frequent:
AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
AFT Pharmaceuticals, Ltd. has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia, Iron-Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06146608Cornell UniversityHeme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption | 2027-01-14 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT07816601AdventHealthDonor Breast Milk 2 | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 134 studies in Anemia, Iron-Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are:
Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.
Iron is essential for the normal functioning of a human body. Iron deficiency anemia (IDA) occurs when blood lacks adequate healthy red blood cells, preventing adequate distribution of oxygen throughout the tissue of the body.
IDA, if left uncorrected, may result in complications such as extreme fatigue, weakness, chest pain, shortness of breath, irregular heartbeats or even heart failure in some cases, in addition to reducing the overall quality of life of a patient. Iron supplementation can effectively treat IDA. An iron-rich diet is known to enhance iron levels, however supplementation is limited by the bio-availability of iron compounds. Oral iron treatment is the most common form of therapy for iron supplementation. However, oral iron supplementation is not ideal for all patients, as adverse events are common, and some patients also fail to respond. Common adverse events (AEs) include significant gastrointestinal discomfort, metallic taste and staining of teeth, resulting in patience discontinuing the treatment. Intravenous (i.v) iron therapy is regarded as a safe method to correct anemia resulting from several conditions that avoids many of the gastrointestinal AEs common with oral iron supplementation.
Ferric carboxymaltose is an established i.v iron formulation approved to treat IDA in Europe and USA. In patients with high iron need, ferric carboxymaltose requires at least two injections, at least 7 days apart. A new i.v. iron formulation has been developed, Ferric Bepectate IV Injection. Ferric Bepectate IV Injection has the potential to be dosed at higher volumes compared to other i.v. iron formulations, allowing for patients with high iron needs to only undergo a single infusion, reducing the medical burden on both the patient and the medical system, and providing a rapid improvement to IDA and associated symptoms.
The current phase 3 study aims to compare Ferric Bepectate IV Injection with two Ferric carboxymaltose formulations (comparators: Ferinject® and Injectafer®) to determine non-inferiority between the Ferric Bepectate IV Injection single dose administration and the current approved dosing for the comparators. A comparison between treatments of the change of hemoglobin (Hb) from baseline after 6 weeks will be the primary outcome. Safety of each treatment will also be assessed to determine superiority, by examining the number of adverse events in the 2 hour period following the beginning of infusion. Key secondary safety endpoints will assess the difference in volume-corrected urine iron after i.v administration, and incidence of hypophosphatemia during the 6 week follow-up period.
A two-dose administration of Ferric Bepectate IV Injection will also be assessed to compare efficacy, tolerance, and safety with the single-dose administration and the comparators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with any to the products, e.g.,
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 2000 mg per dose.
Drug: Ferric Bepectate IV Injection
Single dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 2000 mg per dose.
Drug: Ferric Bepectate IV Injection
Two dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 1000 mg per dose.
Drug: Ferric Bepectate IV Injection
Two dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.
Drug: Ferric Bepectate IV Injection
Two dose ferric carboxymaltose active comparator treatment for USA and Japan. 50 mg iron/mL. Up to 750 mg per dose.
Drug: Ferric Carboxymaltose Injection [Injectafer®]
Two dose ferric carboxymaltose active comparator treatment for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.
Drug: Ferric Carboxymaltose Injection [Ferinject]
Ferric Bepectate IV Injection 50 mg iron/mL
Also known as: Feramyl, Ferric bepectate
Ferric carboxymaltose (Ferinject®) 50 mg iron/mL in two doses 7-9 days apart
Also known as: Ferinject
Ferric carboxymaltose (Injectafer®) 50 mg iron/mL in two doses 7-9 days apart
Also known as: Injectafer
Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatment
The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Injectafer
Time frame: 6 weeks
Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatment
The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Ferinject
Time frame: 6 weeks
Incidence of treatment emergent adverse events
Incidence of treatment emergent adverse events (TEAE) during the 2 hours following the start of infusion
Time frame: 2 hours post infusion start
Blood hemoglobin amount
Mean blood hemoglobin at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
Time frame: 6 weeks
Hemoglobin change from baseline
Mean change in blood hemoglobin from baseline to weeks 1, 2, 4 and 6.
Time frame: 6 weeks
Serum iron change from baseline
Mean change in serum iron from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
Time frame: 6 weeks
Serum ferritin change from baseline
Mean change in serum ferritin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
Time frame: 6 weeks
Serum transferrin change from baseline
Mean change in serum transferrin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
Time frame: 6 weeks
Serum transferrin saturation change from baseline
Mean change in serum transferrin saturation (TSAT) from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
Time frame: 6 weeks
Response Rate
Proportion of patients with normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).
Time frame: 6 weeks
Time to normalization of hemoglobin
Time to normalization normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).
Time frame: 6 weeks
Change in fatigue symptoms
Change in fatigue symptoms from baseline at week 6 measured by the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue). A final score of 0-52 is calculated, where a high score indicates better quality of life.
Time frame: 6 weeks
Incidence of hypophosphatemia
Incidence of hypophosphatemia (serum phosphate \< 2 mg/dL) at any time during the follow-up period (baseline - week 6)
Time frame: 6 weeks
Volume-corrected urine iron amount
Pre- and post-difference of volume-corrected urine iron levels measured before and in the first urine after the end of i.v. administration, (volume corrected iron urine is defined as the ratio between urine iron and urine creatinine)
Time frame: 2 hours
Adverse event severity
Severity of treatment emergent adverse events (TEAEs) during the 2 hours following infusion start
Time frame: 2 hours following infusion start
Adverse event incidence and severity
Incidence and severity of TEAEs during the entire study period (screening - V5)
Time frame: 6 weeks
Treatment related adverse event incidence and severity
Incidence and severity of AEs classified as possibly, probably or definitely related to the study drug (Treatment related adverse events; TRAE) during the study period (screening - V5)
Time frame: 6 weeks
Incidence of injection/infusion site reactions and hypersensitivity reactions
Incidence of injection/infusion site reactions and hypersensitivity reactions
Time frame: 2 hours following infusion start
Change in serum phosphate
Mean change in serum phosphate from baseline to week 6
Time frame: 6 weeks
Change in serum calcium
Mean change in serum calcium from baseline to week 6
Time frame: 6 weeks
ECG changes
Electrocardiogram (ECG) changes from baseline at week 1, 2, 4 and 6. The ECG will specifically assess the following parameters: * Heart Rate * QT interval * ST depression * T wave inversion * Prescence of tachycardia * Left ventricular hypertrophy * Investigator interpretation (normal, abnormal NCS, abnormal CS)
Time frame: 6 weeks
ECG and Hemoglobin relationship
Relation between electrocardiogram (ECG) investigator interpretation (normal, abnormal NCS, abnormal CS) and hemoglobin at baseline and End of Treatment
Time frame: 6 weeks
Pooled data hemoglobin amount
Mean hemoglobin at weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Pooled data change in hemoglobin
Mean change in hemoglobin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Pooled data change in serum iron
Mean change in serum iron from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Pooled data change in serum ferritin
Mean change in serum ferritin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Pooled data change in serum transferrin
Mean change in serum transferrin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Pooled data change in serum transferrin saturation
Mean change in serum transferrin saturation (TSAT) from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Proportion of patients requiring blood transfusion
Proportion of patients who require red blood cell transfusion up to week 6. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Duration of hospital stay
Duration of hospital stay (days), if applicable. Pooled data (USA+Japan+RoW) between study regions.
Time frame: 6 weeks
Plan to share: Undecided — The results of the study may be published in a scientific journal, however individual patient data will not be used, rather data will be provided as descriptive statistics (mean, median, IQR) as required.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 19 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric bepectate
AFT Pharmaceuticals, Ltd.